Loureirin ACAS# 119425-89-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 119425-89-7 | SDF | Download SDF |
PubChem ID | 5319081 | Appearance | White powder |
Formula | C17H18O4 | M.Wt | 286.3 |
Type of Compound | Chalcones | Storage | Desiccate at -20°C |
Synonyms | 4'-Hydroxy 2,4-dimethoxydihydrochalcone | ||
Solubility | DMSO : ≥ 86.6 mg/mL (302.46 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 3-(2,4-dimethoxyphenyl)-1-(4-hydroxyphenyl)propan-1-one | ||
SMILES | COC1=CC(=C(C=C1)CCC(=O)C2=CC=C(C=C2)O)OC | ||
Standard InChIKey | RSAIVLRELNGZEY-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C17H18O4/c1-20-15-9-5-13(17(11-15)21-2)6-10-16(19)12-3-7-14(18)8-4-12/h3-5,7-9,11,18H,6,10H2,1-2H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Loureirin A has an inhibitory effect on platelet activation, perhaps through an impairment of PI3K/Akt signaling. Loureirin A activates Wnt/-catenin pathway and promotes hair follicle stem cells (FSCs)-seeded tissue-engineered skin to repair skin wound.The molecular mechanism of Loureirin A and Wnt signaling pathway mediated anti- hepatic fibrosis and anti- angiogenesis may involve down- regulation the expression of Frizzled- 4,inhibiting the synthesis and secretion of α- SMA,TGF- β1and the proliferation of HSCs. |
Targets | Akt | PI3K | c-Myc | GSK-3 | Wnt/β-catenin | TGF-β/Smad | Frizzled- 4 |
In vitro | Antiplatelet activity of loureirin A by attenuating Akt phosphorylation: In vitro studies.[Pubmed: 25445049]Eur J Pharmacol. 2015 Jan 5;746:63-9.Loureirin A is a flavonoid extracted from Dragon׳s Blood that has been used to promote blood circulation and remove stasis in Chinese traditional medicine. However, the mechanisms of these effects are not fully understood. Effect of Loureirin A on Proliferation and Frizzled-4Expression of Rat Hepatic Stellate Cells in vitro[Reference: WebLink]Journal of Kunming Medical University, 2016 , 37 (6) :13-17.To investigate the molecular mechanism of Loureirin A mediated anti- hepatic fibrosis by evaluting its effects on proliferation,secretion of α- smooth muscle actin(α- SMA) and transforming growth factor- beta1(TGF- β1), and expression of rat hepatic stellate cells in vitro. |
Animal Research | Loureirin A Activates Wnt/β-Catenin Pathway to Promote Wound with Follicle Stem Cell-Seeded Tissue-Engineered Skin Healing[Reference: WebLink]Journal of Biomaterials & Tissue Engineering, 2016 , 6 (6) :427-432.Hair follicle stem cells (FSCs) can participate in the formation of hair follicles and epidermis. FSCs are well known as the ideal seed cells for tissue-engineered skin. Loureirin A, the major constituent of resina draconis, can promote skin wound healing. |
Structure Identification | Eur J Med Chem. 2015 Mar 26;93:492-500.Comparison between loureirin A and cochinchinenin C on the interaction with human serum albumin.[Pubmed: 25734332]
|
Loureirin A Dilution Calculator
Loureirin A Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.4928 mL | 17.4642 mL | 34.9284 mL | 69.8568 mL | 87.321 mL |
5 mM | 0.6986 mL | 3.4928 mL | 6.9857 mL | 13.9714 mL | 17.4642 mL |
10 mM | 0.3493 mL | 1.7464 mL | 3.4928 mL | 6.9857 mL | 8.7321 mL |
50 mM | 0.0699 mL | 0.3493 mL | 0.6986 mL | 1.3971 mL | 1.7464 mL |
100 mM | 0.0349 mL | 0.1746 mL | 0.3493 mL | 0.6986 mL | 0.8732 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Loureirin A is a flavonoid extracted from Dragon's Blood, can inhibit Akt phosphorylation, and has antiplatelet activity.
In Vitro:Loureirin A (50 μM, 100 μM) inhibits collagen-induced platelet ATP secretion and thrombin-stimulated P-selectin expression in a dose-dependent manner. Loureirin A also significantly impairs platelet spreading on immobilized fibrinogen. Loureirin A almost completely eliminates collagen-induced Akt phosphorylation at Ser473 at the dose of 100 μM, and has an additive inhibitory effect with the phosphoinositide 3-kinase (PI3K) inhibitor Ly294002 on collage-induced Akt phosphorylation in platelets at 50 μM[1].
References:
[1]. Hao HZ, et al. Antiplatelet activity of loureirin A by attenuating Akt phosphorylation: In vitro studies. Eur J Pharmacol. 2015 Jan 5;746:63-9.
- Galanin (1-30) (human)
Catalog No.:BCC6961
CAS No.:119418-04-1
- Licoricesaponin E2
Catalog No.:BCN7894
CAS No.:119417-96-8
- Topotecan hydrochloride
Catalog No.:BCN2604
CAS No.:119413-54-6
- LY2811376
Catalog No.:BCC2102
CAS No.:1194044-20-6
- Przewalskin
Catalog No.:BCN6080
CAS No.:119400-87-2
- Salviolone
Catalog No.:BCN3141
CAS No.:119400-86-1
- 2,5-Dihydroxybenzaldehyde
Catalog No.:BCN6081
CAS No.:1194-98-5
- mAChR-IN-1
Catalog No.:BCC5512
CAS No.:119391-56-9
- 2-Deacetoxytaxinine J
Catalog No.:BCN7291
CAS No.:119347-14-7
- CRANAD 2
Catalog No.:BCC6293
CAS No.:1193447-34-5
- 2-Hydroxydiplopterol
Catalog No.:BCN7290
CAS No.:1193250-54-2
- Olean-12-ene-3,24-diol
Catalog No.:BCN6079
CAS No.:119318-15-9
- Loureirin B
Catalog No.:BCN5021
CAS No.:119425-90-0
- Eliprodil
Catalog No.:BCC7280
CAS No.:119431-25-3
- Fruquintinib(HMPL-013)
Catalog No.:BCC6415
CAS No.:1194506-26-7
- Meropenem trihydrate
Catalog No.:BCC4226
CAS No.:119478-56-7
- Ethyllucidone
Catalog No.:BCN6082
CAS No.:1195233-59-0
- Ceanothic acid acetate
Catalog No.:BCN6083
CAS No.:119533-63-0
- Othonnine
Catalog No.:BCN2061
CAS No.:119565-25-2
- N,N-Dimethylsphingosine
Catalog No.:BCC7959
CAS No.:119567-63-4
- 11-Hydroxygelsenicine
Catalog No.:BCN4761
CAS No.:1195760-68-9
- Dabrafenib (GSK2118436)
Catalog No.:BCC4393
CAS No.:1195765-45-7
- Dabrafenib Mesylate (GSK-2118436)
Catalog No.:BCC1513
CAS No.:1195768-06-9
- 7-Ethyl-10-Hydroxy-Camptothecin
Catalog No.:BCN8386
CAS No.:119577-28-5
Antiplatelet activity of loureirin A by attenuating Akt phosphorylation: In vitro studies.[Pubmed:25445049]
Eur J Pharmacol. 2015 Jan 5;746:63-9.
Loureirin A is a flavonoid extracted from Dragons Blood that has been used to promote blood circulation and remove stasis in Chinese traditional medicine. However, the mechanisms of these effects are not fully understood. We explored the anti-platelet activity and underlying mechanism of Loureirin A in vitro. Our results indicated that Loureirin A negatively affected agonist-induced platelet aggregation such as collagen, collagen-related peptide (CRP), ADP and thrombin. Loureirin A inhibited collagen-induced platelet ATP secretion and thrombin-stimulated P-selectin expression in a dose-dependent manner. Platelet spreading on immobilized fibrinogen was significantly impaired in the presence of Loureirin A. Immunoblotting analysis indicated that 100muM of Loureirin A almost completely eliminated collagen-induced Akt phosphorylation at Ser473. Interestingly, a submaximal dose (50muM) of Loureirin A had an additive inhibitory effect with the phosphoinositide 3-kinase (PI3K) inhibitor Ly294002 on collage-induced Akt phosphorylation in platelets. Taken together, Loureirin A had an inhibitory effect on platelet activation, perhaps through an impairment of PI3K/Akt signaling.
Comparison between loureirin A and cochinchinenin C on the interaction with human serum albumin.[Pubmed:25734332]
Eur J Med Chem. 2015 Mar 26;93:492-500.
The interactions of Loureirin A (LA) and cochinchinenin C (CC) with human serum albumin (HSA) under simulated physiological conditions (pH = 7.4) have been studied with fluorescence, UV-vis absorption spectroscopic method and molecular docking technique. The results indicated that there was a synergistic interaction between LA and CC, and the fluorescence quenching of HSA by LA (or CC) was a combined quenching procedure (dynamic and static quenching). At low compound concentrations, the quenching constants KSV of CC was larger than that of LA, which meant the CC efficacy may be better than that of LA. The negative big up tri, openH and big up tri, openS values suggested hydrogen bonds and van der Waals forces played the major role in the binding of LA (or CC) to HSA. The efficiency of energy transfer and distance between the compounds and HSA was calculated. Moreover, the results of synchronous and three-dimensional fluorescence demonstrated that the HSA microenvironment was changed in the presence of LA (or CC). Finally, the binding of LA (or CC) to HSA was modeled by molecular docking, which is in good accordance with the experimental studies.